Patient characteristics
| Patient no. . | Sex, age, y . | HLA type . | Prior therapy . | Pretreatment karyotype . | CR (before vaccine), mo . |
|---|---|---|---|---|---|
| 1 | M/69 | A1101/2902; B1402/5201; DRb1*0701/1502; DQb1*0202/0601 C0802/1202 | 3+5; HiDAC × 2 | nl | 5 |
| 2† | F/42 | A2401/0201; B3906/1402; C0702/1505; DRb*0102/1104; DQb*0501/0301 | 3+5; HiDAC × 4 | nl | 12 |
| 3 | M/70 | A0101/2601; B3701/4501; C0602/0602; DRb1*0101/1501; DQb1*0501/0602 | 3+5; 2+4 × 2 | nl | 6 |
| 4† | F/44 | A0201/0302; B1302/3801; C0602/1203; DRb1*0701/1301; DQb1*0202/0603 | 3+5; 2+4 × 1; HiDAC × 3 | nl | 10 |
| 5† | M/64 | A0101/0201; B0801/4402; C0701/0501; DRb1*0301/0401; DQb1*0201/0301 | 3+5; HiDAC × 4 | inv16 | 10 |
| 6 | F/67 | A0101/2601; B0801/3801; C0701/1203; DRb1*0301/1301; DQb1*0201/0603 | 3+5; 2+4 × 2 | F | 12 |
| 7 | M/76 | A2301/2402; B1402/3502; C0802/0401; DRb1*0102/1201; DQb1*0501/0301 | 3+5; 2+4 × 2 | nl | 7 |
| 8 | M/22 | A2402/3201; B: 1501/4402; C0303/0501; DRb1*0101/0406; DQb1*0501/0302 | 3+7; 2+5; HiDAC × 4 | nl | 12 |
| 9 | M/49 | A0101/2402; B35014002; C0401/0202; DRb1*0101/1601; DQb1*0501/0502 | 3+7; HiDAC × 4 | nl | 16 |
| Patient no. . | Sex, age, y . | HLA type . | Prior therapy . | Pretreatment karyotype . | CR (before vaccine), mo . |
|---|---|---|---|---|---|
| 1 | M/69 | A1101/2902; B1402/5201; DRb1*0701/1502; DQb1*0202/0601 C0802/1202 | 3+5; HiDAC × 2 | nl | 5 |
| 2† | F/42 | A2401/0201; B3906/1402; C0702/1505; DRb*0102/1104; DQb*0501/0301 | 3+5; HiDAC × 4 | nl | 12 |
| 3 | M/70 | A0101/2601; B3701/4501; C0602/0602; DRb1*0101/1501; DQb1*0501/0602 | 3+5; 2+4 × 2 | nl | 6 |
| 4† | F/44 | A0201/0302; B1302/3801; C0602/1203; DRb1*0701/1301; DQb1*0202/0603 | 3+5; 2+4 × 1; HiDAC × 3 | nl | 10 |
| 5† | M/64 | A0101/0201; B0801/4402; C0701/0501; DRb1*0301/0401; DQb1*0201/0301 | 3+5; HiDAC × 4 | inv16 | 10 |
| 6 | F/67 | A0101/2601; B0801/3801; C0701/1203; DRb1*0301/1301; DQb1*0201/0603 | 3+5; 2+4 × 2 | F | 12 |
| 7 | M/76 | A2301/2402; B1402/3502; C0802/0401; DRb1*0102/1201; DQb1*0501/0301 | 3+5; 2+4 × 2 | nl | 7 |
| 8 | M/22 | A2402/3201; B: 1501/4402; C0303/0501; DRb1*0101/0406; DQb1*0501/0302 | 3+7; 2+5; HiDAC × 4 | nl | 12 |
| 9 | M/49 | A0101/2402; B35014002; C0401/0202; DRb1*0101/1601; DQb1*0501/0502 | 3+7; HiDAC × 4 | nl | 16 |
3+5 indicates idarubicin 12 mg/m2 × 3 days and cytarabine 200 mg/m2 × 5 days; HiDAC, cytarabine 3 g/m2 every 12 hours on days 1, 3, and 5; 2+4, idarubicin 12 mg/m2 × 2 days and cytarabine 200 mg/m2 × 4 days; 3+7, daunorubicin 60 mg/m2 × 3 days and cytarabine 200 mg/m2 × 7 days; 2+5, daunorubicin 60 mg/m2 × 2 days and cytarabine 200 mg/m2 × 5 days; nl, normal; and F, failure.
HLA-A0201 patient.